Prophylactic Administration of Surfactant in Extremely Premature Infants
Objective. To investigate whether prophylactic surfactant administration is superior over selective treatment in preterm infants with respiratory distress syndrome (RDS). Methods. In our retrospective analysis, we compared premature infants (23 + 0 to 26 + 6 weeks) receiving 200 mg/kg surfactant (cu...
Saved in:
Main Authors: | , , , , |
---|---|
Format: | Article |
Language: | English |
Published: |
Wiley
2010-01-01
|
Series: | Critical Care Research and Practice |
Online Access: | http://dx.doi.org/10.1155/2010/235894 |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
_version_ | 1832554365740646400 |
---|---|
author | Lutz Koch David Frommhold Bernd Beedgen Peter Ruef Johannes Poeschl |
author_facet | Lutz Koch David Frommhold Bernd Beedgen Peter Ruef Johannes Poeschl |
author_sort | Lutz Koch |
collection | DOAJ |
description | Objective. To investigate whether prophylactic surfactant administration is superior over selective treatment in preterm infants with respiratory distress syndrome (RDS). Methods. In our retrospective analysis, we compared premature infants (23 + 0 to 26 + 6 weeks) receiving 200 mg/kg surfactant (curosurf0𝑥000𝑎𝑒) within five minutes after birth (prophylactic group, 𝑁=31) with those infants who received surfactant therapy for established RDS (selective group, 𝑁=34).
Results. Prophylactic therapy significantly decreased the need for mechanical ventilation (74 hours per patient versus 171 hours per patient, resp.). We observed a reduced incidence of interstitial emphysema (0% versus 9%, resp.), pneumothoraces (3% versus 9%, resp.), chronic lung disease (26% versus 38%, resp.), and surfactant doses per patient (1.3 versus 1.8, resp.), although those variables did not reach significance. Conclusion. We conclude that infants under 27 weeks' gestation profit from prophylactic surfactant administration by reducing the time of mechanical ventilation. This in turn could contribute to reduce the risk for mechanical ventilation associated complications, without any detrimental short-term side effects. |
format | Article |
id | doaj-art-7916aed201b64e73a0d5cfd7367b5eed |
institution | Kabale University |
issn | 2090-1305 2090-1313 |
language | English |
publishDate | 2010-01-01 |
publisher | Wiley |
record_format | Article |
series | Critical Care Research and Practice |
spelling | doaj-art-7916aed201b64e73a0d5cfd7367b5eed2025-02-03T05:51:45ZengWileyCritical Care Research and Practice2090-13052090-13132010-01-01201010.1155/2010/235894235894Prophylactic Administration of Surfactant in Extremely Premature InfantsLutz Koch0David Frommhold1Bernd Beedgen2Peter Ruef3Johannes Poeschl4Division of Neonatology, Department of Pediatrics, University of Heidelberg Medical School, Im Neuenheimer Feld 430, 69120 Heidelberg, GermanyDivision of Neonatology, Department of Pediatrics, University of Heidelberg Medical School, Im Neuenheimer Feld 430, 69120 Heidelberg, GermanyDivision of Neonatology, Department of Pediatrics, University of Heidelberg Medical School, Im Neuenheimer Feld 430, 69120 Heidelberg, GermanyDivision of Neonatology, Department of Pediatrics, University of Heidelberg Medical School, Im Neuenheimer Feld 430, 69120 Heidelberg, GermanyDivision of Neonatology, Department of Pediatrics, University of Heidelberg Medical School, Im Neuenheimer Feld 430, 69120 Heidelberg, GermanyObjective. To investigate whether prophylactic surfactant administration is superior over selective treatment in preterm infants with respiratory distress syndrome (RDS). Methods. In our retrospective analysis, we compared premature infants (23 + 0 to 26 + 6 weeks) receiving 200 mg/kg surfactant (curosurf0𝑥000𝑎𝑒) within five minutes after birth (prophylactic group, 𝑁=31) with those infants who received surfactant therapy for established RDS (selective group, 𝑁=34). Results. Prophylactic therapy significantly decreased the need for mechanical ventilation (74 hours per patient versus 171 hours per patient, resp.). We observed a reduced incidence of interstitial emphysema (0% versus 9%, resp.), pneumothoraces (3% versus 9%, resp.), chronic lung disease (26% versus 38%, resp.), and surfactant doses per patient (1.3 versus 1.8, resp.), although those variables did not reach significance. Conclusion. We conclude that infants under 27 weeks' gestation profit from prophylactic surfactant administration by reducing the time of mechanical ventilation. This in turn could contribute to reduce the risk for mechanical ventilation associated complications, without any detrimental short-term side effects.http://dx.doi.org/10.1155/2010/235894 |
spellingShingle | Lutz Koch David Frommhold Bernd Beedgen Peter Ruef Johannes Poeschl Prophylactic Administration of Surfactant in Extremely Premature Infants Critical Care Research and Practice |
title | Prophylactic Administration of Surfactant in Extremely Premature Infants |
title_full | Prophylactic Administration of Surfactant in Extremely Premature Infants |
title_fullStr | Prophylactic Administration of Surfactant in Extremely Premature Infants |
title_full_unstemmed | Prophylactic Administration of Surfactant in Extremely Premature Infants |
title_short | Prophylactic Administration of Surfactant in Extremely Premature Infants |
title_sort | prophylactic administration of surfactant in extremely premature infants |
url | http://dx.doi.org/10.1155/2010/235894 |
work_keys_str_mv | AT lutzkoch prophylacticadministrationofsurfactantinextremelyprematureinfants AT davidfrommhold prophylacticadministrationofsurfactantinextremelyprematureinfants AT berndbeedgen prophylacticadministrationofsurfactantinextremelyprematureinfants AT peterruef prophylacticadministrationofsurfactantinextremelyprematureinfants AT johannespoeschl prophylacticadministrationofsurfactantinextremelyprematureinfants |